Salvo Health announces the first-to-market RPM offering for GI chronic conditions, including IBS, GERD/reflux, dyspepsia, Celiac, SIBO, and more to optimize clinical outcomes and boost practices for participating partners.
In 2022 alone, the Remote Patient Monitoring (RPM) market grew to over $50 billion with the market set to exceed $175 billion by the year 2027.1 In recent years, numerous medical studies have concluded better health outcomes and lower costs as a result of RPM programs.2 For providers and payers, treatment plans consisting of RPM for conditions such as diabetes, hypertension, congestive heart failure, and COPD have seen massive improvements in clinical outcomes while yielding cost-savings, and yet RPM had yet to be offered in GI…until now.
Today, Salvo Health announces the first-ever RPM offering for chronic GI conditions, including IBS, GERD/reflux, dyspepsia, Celiac, SIBO, and more. This new offering seeks to not only optimize better clinical outcomes for patients but increase practice reach and annual revenue for participating partners.
The Salvo Health GI RPM offering is a white-label/co-branded service offered through local GI practices and GI departments at hospital systems. Participating, in-person GIs maintain current patient-provider relationships (including billing), while allowing Salvo to provide additional staffing, technology, home medical devices, and digital content - under the direct supervision of the GI partner.
Through this offering, our Salvo Health clinical team will:
Central to our RPM program offering is the belief that monitoring alone is insufficient to drive better outcomes. Our comprehensive approach pairs RPM enablement with intensive, evidence-based practices in behavior change, nutrition, GI-directed psychology, and daily symptom tracking to equip patients with the means to manage symptoms and stress responses.
Studies show increases in HRV over time are closely associated with improved nutrition and psychological health, both tied closely to GI symptoms mediated by the Vagus Nerve3 while HRV tends to run lower in those with IBD and IBS symptoms.4 In addition, gut health problems have been tightly linked to anxiety and depression,5 in a vicious circle of cause and effect, with studies showing lower HRV prevalent in patients with anxiety symptoms.6
By monitoring daily HRV over a period of months while recording adherence to nutrition, lifestyle, and behavior changes, providers can more accurately track improvement between physical and psychological symptoms plaguing many chronic GI sufferers to inform treatment plan adjustments and service better clinical outcomes. In addition, as a recent study noted, "It is advisable to include HRV measurements as a measure of the effectiveness of interventions in IBS therapy, and to assess autonomic changes as a moderator of the effectiveness of IBS therapy.
If you are a GI practice or health system GI division interested in learning more about leveraging Salvo’s provider enablement, please see our Provider page or reach out to email@example.com.
Salvo Health is backed by a $10.5 million investment from the investors and founders behind such innovative health tech companies as Livongo, Tia, Forward, Ginger, Ro, and others. For more information on the company, please see our About Us.